Literature DB >> 36271155

Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.

Xiaolong Gu1, Xianbo Yu2, Gaofeng Shi3, Yang Li1, Li Yang1.   

Abstract

BACKGROUND: This study aimed to construct a computed tomography (CT) radiomics model to predict programmed cell death-ligand 1 (PD-L1) expression in gastric adenocarcinoma patients using radiomics features.
METHODS: A total of 169 patients with gastric adenocarcinoma were studied retrospectively and randomly divided into training and testing datasets. The clinical data of the patients were recorded. Radiomics features were extracted to construct a radiomics model. The random forest-based Boruta algorithm was used to screen the features of the training dataset. A receiver operating characteristic (ROC) curve was used to evaluate the predictive performance of the model.
RESULTS: Four radiomics features were selected to construct a radiomics model. The radiomics signature showed good efficacy in predicting PD-L1 expression, with an area under the receiver operating characteristic curve (AUC) of 0.786 (p < 0.001), a sensitivity of 0.681, and a specificity of 0.826. The radiomics model achieved the greatest areas under the curve (AUCs) in the training dataset (AUC = 0.786) and testing dataset (AUC = 0.774). The calibration curves of the radiomics model showed great calibration performances outcomes in the training dataset and testing dataset. The net clinical benefit for the radiomics model was high.
CONCLUSION: CT radiomics has important value in predicting the expression of PD-L1 in patients with gastric adenocarcinoma.
© 2022. The Author(s).

Entities:  

Keywords:  Computed tomography; Gastric adenocarcinoma; PD-L1; Radiomics

Year:  2022        PMID: 36271155     DOI: 10.1007/s00261-022-03709-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  24 in total

Review 1.  Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.

Authors:  Yoshiaki Nakamura; Akihito Kawazoe; Florian Lordick; Yelena Y Janjigian; Kohei Shitara
Journal:  Nat Rev Clin Oncol       Date:  2021-03-31       Impact factor: 66.675

Review 2.  Current treatment and recent progress in gastric cancer.

Authors:  Smita S Joshi; Brian D Badgwell
Journal:  CA Cancer J Clin       Date:  2021-02-16       Impact factor: 508.702

3.  Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.

Authors:  Qiang Wen; Zhe Yang; Honghai Dai; Alei Feng; Qiang Li
Journal:  Front Oncol       Date:  2021-08-06       Impact factor: 6.244

4.  Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.

Authors:  Zongqiong Sun; Shudong Hu; Yuxi Ge; Jun Wang; Shaofeng Duan; Jiayang Song; Chunhong Hu; Yonggang Li
Journal:  J Xray Sci Technol       Date:  2020       Impact factor: 1.535

5.  Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.

Authors:  Kye Jin Park; Jae-Lyun Lee; Shin-Kyo Yoon; Changhoe Heo; Bum Woo Park; Jeong Kon Kim
Journal:  Eur Radiol       Date:  2020-05-12       Impact factor: 5.315

6.  Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

Authors:  Ronan J Kelly; Jeeyun Lee; Yung-Jue Bang; Khaldoun Almhanna; Mariela Blum-Murphy; Daniel V T Catenacci; Hyun Cheol Chung; Zev A Wainberg; Michael K Gibson; Keun-Wook Lee; Johanna C Bendell; Crystal S Denlinger; Cheng Ean Chee; Takeshi Omori; Rom Leidner; Heinz-Josef Lenz; Yee Chao; Marlon C Rebelatto; Philip Z Brohawn; Peng He; Jennifer McDevitt; Siddharth Sheth; Judson M Englert; Geoffrey Y Ku
Journal:  Clin Cancer Res       Date:  2019-11-01       Impact factor: 12.531

7.  Investigation of the role of feature selection and weighted voting in random forests for 3-D volumetric segmentation.

Authors:  M Yaqub; M K Javaid; C Cooper; J A Noble
Journal:  IEEE Trans Med Imaging       Date:  2013-10-02       Impact factor: 10.048

8.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Authors:  Yelena Y Janjigian; Kohei Shitara; Markus Moehler; Marcelo Garrido; Pamela Salman; Lin Shen; Lucjan Wyrwicz; Kensei Yamaguchi; Tomasz Skoczylas; Arinilda Campos Bragagnoli; Tianshu Liu; Michael Schenker; Patricio Yanez; Mustapha Tehfe; Ruben Kowalyszyn; Michalis V Karamouzis; Ricardo Bruges; Thomas Zander; Roberto Pazo-Cid; Erika Hitre; Kynan Feeney; James M Cleary; Valerie Poulart; Dana Cullen; Ming Lei; Hong Xiao; Kaoru Kondo; Mingshun Li; Jaffer A Ajani
Journal:  Lancet       Date:  2021-06-05       Impact factor: 79.321

9.  Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.

Authors:  Katrin Aslan; Verena Turco; Jens Blobner; Jana K Sonner; Anna Rita Liuzzi; Nicolás Gonzalo Núñez; Donatella De Feo; Philipp Kickingereder; Manuel Fischer; Ed Green; Ahmed Sadik; Mirco Friedrich; Khwab Sanghvi; Michael Kilian; Frederik Cichon; Lara Wolf; Kristine Jähne; Anna von Landenberg; Lukas Bunse; Felix Sahm; Daniel Schrimpf; Jochen Meyer; Allen Alexander; Gianluca Brugnara; Ralph Röth; Kira Pfleiderer; Beate Niesler; Andreas von Deimling; Christiane Opitz; Michael O Breckwoldt; Sabine Heiland; Martin Bendszus; Wolfgang Wick; Burkhard Becher; Michael Platten
Journal:  Nat Commun       Date:  2020-02-18       Impact factor: 14.919

10.  Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.

Authors:  Min Zhang; Shuofeng Hu; Min Min; Bing Liu; Xiaomin Ying; Yan Liu; Yanli Ni; Zheng Lu; Xiaotian Sun; Jiaqi Wu
Journal:  Gut       Date:  2020-06-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.